glp-1 receptor agonist long term side effects Comparative safety and of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management A clinician's perspective 📝 GLP-1

Alzheimers Dement (2020) 16(9):131229

This glucagon-like peptide-1 (GLP-1) agonist has been hailed as a game changer due to its properties and significant clinical benefits

However, although the data obtained from preclinical studies involving a relatively small number of healthy subjects are promising, further comparative trials in larger populations of people with T2DM and obesity are required to confirm the therapeutic potential of this new GLP-1, GIP, and GCG receptor tri-agonist, particularly in comparison with existing selective GLP-1 and dual GLP-1/GIP receptor agonists

The combined receptor activation produces measurable outcomes distinct from single or dual-receptor activation alone

Disclosures Andr J

N Engl J Med 2024;391:109-21.ArticlePubMed 77